|
Company > Collaborations
Pharmaceutical Company Collaborations
Federal
CombinatoRx collaborates with pharmaceutical and biotechnology companies to support the full development and commercialization of selected product candidates to obtain access to additional development, financial or commercial resources including sales forces.
Pharmaceutical Corporation Collaborations
Novartis
In May 2009, CombinatoRx and Novartis entered into a strategic alliance focused on the discovery of novel anti-cancer combinations. The collaboration explores combination effects in cell lines representing a broad spectrum of cancers to provide a robust and systematic understanding of combination therapy opportunities. The alliance also explores important differences in response by cancer type, including genotype and other mutational differences. Each party will contribute compounds from its compound library and evaluate the anti-cancer effects by utilizing CombinatoRx’s proprietary combination high throughput screening (cHTS™) platform and Chalice analyzer software.
Under the agreement, CombinatoRx received a $4 million upfront payment and funding for research support for two years. In addition, for each combination advanced to the market from the collaboration, CombinatoRx is eligible to receive up to $58 million in clinical, regulatory and commercial milestones. The alliance has an initial two-year term that may be extended by Novartis for three additional one-year periods. CombinatoRx retains the right to conduct oncology research on its own behalf as well as partner with others in the field of oncology, and will retain certain intellectual property rights which may arise from the collaboration research.
Fovea Pharmaceuticals SA
In January 2006, CombinatoRx entered into a research and license agreement with Fovea Pharmaceuticals in which Fovea agreed to fund and develop selected CombinatoRx product candidates for ophthalmic diseases up to the start of Phase III trials, including Prednisporin™ (FOV1101), a product candidate being developed by Fovea to treat allergic conjunctivitis. Under the agreement, CombinatoRx granted Fovea an exclusive worldwide license to Prednisporin (FOV-1101) certain other drug combinations to treat allergic and inflammatory diseases of the front of the eye. Fovea has advanced Prednisporin through a Phase 2a proof-of-concept clinical trial for allergic conjunctivitis. For these licensed combinations, CombinatoRx has received payments totaling $1.0 million, and is eligible to receive up to $24.75 million in development and regulatory milestone payments for each combination successfully developed by Fovea, an additional $15.0 million milestone payment for the approval of a combination in a specified additional indication and in the event these exclusively licensed combinations are licensed by Fovea to a third party, commercialization milestones of up to an additional $25.0 million. CombinatoRx is also eligible to receive royalties for each product commercialized by Fovea in connection with the agreement. Fovea has agreed to be acquired by Sanofi Aventis, in a transaction expected to close during 2009.
Mallinckrodt, Inc.
In June 2009, we sold the U.S. rights to our lead investigational drug candidate, Exalgo™(hydromorphone HCl) Extended-Release Tablets [CII], to Covidien's subsidiary Mallinckrodt Inc. Under the terms of the agreement, we have received a one-time upfront payment. In addition, Neuromed could receive additional development and, if Exalgo is approved, regulatory approval milestone payments, as well as a royalty based on commercial sales of Exalgo.
Clinical Data, Inc.
In August 2009, CombinatoRx and PGxHealth, a subsidiary of Clinical Data, Inc., entered into a Collaboration Agreement relating to the potential development of ATL313, an adenosine A2A receptor agonist compound owned by PGx, as a combination therapy in the cancer field. CombinatoRx has previously discovered that adenosine A2A agonists synergize with existing and emerging standard-of-care drugs for the treatment of multiple myeloma and certain other B-cell malignancies.
Under the agreement, CombinatoRx will fund and advance the preclinical and clinical development of ATL313 as a combination therapy in the cancer field. PGx has an exclusive option exercisable to enter into a co-development relationship with CombinatoRx relating to ATL313 in the cancer field. PGx may exercise the co-development option by paying CombinatoRx 50% of the costs incurred by CombinatoRx to develop ATL313, and PGx would then equally share the costs of further development of ATL313 in cancer. If PGx does not exercise its co-development option, CombinatoRx may maintain its exclusive license to ATL313 in the cancer field by paying PGx a license fee of $5 million. In addition, CombinatoRx would be obligated to pay PGx up to $252.5 million upon the achievement of various clinical and regulatory milestones and upon the achievement of various aggregate net sales milestones for products containing ATL313 in the cancer field. If PGx does not exercise its co-development option, CombinatoRx will pay PGx tiered royalty rates based on annual net sales of products containing ATL313.
Federal
U.S. Army Medical Research Institute for Infectious Diseases
Received a $1.3 million research grant from the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) for the research and discovery of potential treatments for viral hemorrhagic fevers (VHFs). VHFs are caused by several distinct families of viruses that affect multiple organ systems in the body, and are often accompanied by hemorrhage (bleeding). Many of these viruses cause severe, life-threatening disease.
National Institute of Allergy and Infectious Diseases (NIAID)
In April 2005, CombinatoRx was awarded a $4.4 million research grant from the National Institute of Allergy and Infectious Diseases (NIAID) (Full News Release). This cooperative research grant with the National Institute of Health (NIH) will apply the CombinatoRx cHTS™ technology to identify potential anti-toxin therapeutics that could be used to alleviate the life-threatening symptoms associated with anthrax exposure.
If you have business development inquiries, please contact bizdev@combinatorx.com.
|
